Thryv Therapeutics Inc. has secured an exclusive worldwide patent and know-how license for a new class of Serum and Glucocorticoid-regulated Kinase 1 (SGK1) inhibitors from the Spanish National Research Council (CSIC) and the Autonomous University of Madrid (UAM), effective July 1, 2026, and announced in September 2026. This acquisition expands the clinical-stage biopharmaceutical company’s portfolio into neurodegenerative diseases like Parkinson’s and Alzheimer’s, supplementing its ongoing cardiovascular programs.
Expanding the Chemical Horizon Beyond Cardiac Indications
Clinical-stage biopharmaceutical company Thryv Therapeutics Inc. announced an agreement to acquire a structurally distinct class of SGK1 inhibitors developed by Spanish research institutions. The exclusive worldwide license involves the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, CSIC), the Autonomous University of Madrid (UAM), and Fundación de la Universidad Autónoma de Madrid (FUAM). Effective as of July 1, 2026, the deal gives Thryv rights across all fields of use and territories, including the right to sublicense.
Prior to this acquisition, Thryv’s clinical candidates relied on a single in-licensed chemical scaffold supported by more than 500 synthesized analogs. According to company statements, the CSIC and UAM series represents a completely independent chemotype. This distinct chemical starting point allows the company to tailor its chemistry to specific clinical indications, maintaining optimization for cardiac diseases while pursuing compounds designed to reach the brain.
In Plain English: The Clinical Takeaway:
- Targeting the Brain: The newly acquired chemical compounds are designed to reach the brain, reaching neural tissues that Thryv’s older cardiac-focused drugs were not designed to reach.
- Independent Chemistry: Unlike modifying previous formulas, this deal introduces an entirely separate molecular family (chemotype) discovered by European research teams.
- Broad Pipeline: While lead assets continue testing in heart conditions, this expansion lays the groundwork for future clinical trials targeting neurodegenerative diseases.
Cellular Pathways at the Intersection of Neurodegeneration
Activated SGK1 sits at a critical crossroads for several biological mechanisms implicated in neurodegenerative disorders. Published research has connected the kinase to tau phosphorylation, the processing of misfolded and aggregating proteins, neuroinflammatory signaling, and cellular stress responses dependent on FOXO and NRF2 pathways. These pathological features drive neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease, and related tauopathies.
| Asset / Program | Indication | Clinical Status | Chemical Origin |
|---|---|---|---|
| THRV-1268 | Long QT Syndrome Type 2, Heart Failure (ASPIRE-HF) | Phase 2a / WAVE II study | Original in-licensed scaffold (>500 analogs) |
| CSIC/UAM Series | Parkinson’s Disease, Alzheimer’s Disease, Tauopathies | Preclinical / Discovery expansion | Newly licensed Spanish research chemotype |
Balancing Neurodegeneration with Ongoing Cardiovascular Trials
While the new Spanish portfolio opens avenues into neurology, Thryv’s core cardiovascular pipeline maintains active momentum. The company’s lead oral selective SGK1 inhibitor, THRV-1268, is currently undergoing evaluation in the WAVE II clinical trial involving patients diagnosed with Long QT Syndrome Type 2. Additionally, a Phase 2a clinical study titled ASPIRE-HF is planned to evaluate the compound in heart failure patients with a reduced ejection fraction.
Company leadership emphasized the strategic value of adding a second independent series without slowing down existing cardiac programs. Debra Odink, President and Chief Development Officer of Thryv Therapeutics, noted that the organization spent years establishing the clinical validity of SGK1 as an underexploited target in medicine. By integrating the discoveries from CSIC and UAM, the firm gains a methodical framework to evaluate SGK1 biology against neurodegenerative targets.
Contraindications & When to Consult a Doctor
As these therapeutic candidates remain in clinical evaluation and preclinical development, they are not available for public prescription or retail consumption. Patients dealing with neurodegenerative conditions such as Alzheimer’s or Parkinson’s disease, or cardiac irregularities like Long QT Syndrome, should avoid unverified experimental treatments or unapproved supplements claiming to target SGK1 pathways. Always consult a qualified neurologist, cardiologist, or primary care physician before altering any established medication regimens or participating in clinical trials.
References
- Thryv Therapeutics Inc. Corporate News and Press Releases: “Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain’s CSIC and Universidad Autónoma de Madrid.” September 2026.
- Consejo Superior de Investigaciones Científicas (CSIC) & Centro de Investigaciones Biológicas Margarita Salas: Collaborative Research Publications on SGK1 Kinase Signaling and Tauopathies.
- Universidad Autónoma de Madrid (UAM) Institute for Biomedical Research: Neurobiology and Cellular Stress Response Documentation.
Disclaimer: This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
